糖化血红蛋白达标治疗改善初诊2型糖尿病C肽分泌功能的研究

目的探讨初诊2型糖尿病患者接受糖化血红蛋白(HbA1c)≤6.5%达标治疗前后自身C肽分泌功能的变化及意义。方法初诊2型糖尿病患者53例,依据自身C肽分泌水平选择相应的非胰岛素促泌剂药物治疗3~6个月至HbA1c≤6.5%。对治疗前后OGTT-C肽释放试验结果进行比较。结果治疗后0、30、60、120、180min的OGTT血糖值均显著降低(P<0.01);30、60、120min的C肽值均显著升高(P<0.01);FCP/FPG、△C30/△G30、△C60/△G60、△C120/△G120、C180/G180以及2hCP/FCP均显著升高(P<0.01)。结论 HbA1c达标治疗能有效增加初诊2型糖尿病患者葡萄糖刺激的C肽分泌,明显改善C肽分泌模式,有利于控制高血糖病情进展。

The study of c-peptide secretion before and after targeted HbA1c therapy in patients with newly diagnosed type 2 diabetes mellitus

Objective To study the changes and significance of C-peptide secretion function before and after treatment reaching a goal of HbA1C ≤6.5% for patients with newly diagnosed type 2 diabetes mellitus. Methods 53 patients with newly diagnosed type 2 diabetes mellitus received non-insulin secretagogue treatment corresponding to self C-peptide secretion levels for 3～6 months till HbA1C≤6.5%.Compared the outcomes of OGTT-C peptide secreation before treatment with after treatment.Results Compared with before treatment,all of the OGTT blood glucose decreased significantly at time points of 0,30,60,120 and 180 min(P<0.01);C-peptide increased significantly at 30,60 and 120 min time points(P<0.01);the ratios of FCP/FPG,△C30/△G30,△C60/△G60,△C120/△G120,C180/G180 and 2hCP/FCP increased significantly(P<0.01).Conclusion HbA1C targeted therapy(≤6.5%) can significantly stimulate the secretion of C-peptide for patients with newly diagnosed type 2 diabetes mellitus,improve the C-peptide secretion mode and benefit the control of high blood glucose development.